bioAffinity Technologies, Inc. (BIAF)Healthcare | Diagnostics & Research | San Antonio, United States | NasdaqCM
3.56 USD
-0.07
(-1.793%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 3.51 -0.05 (-0.050%) ⇩ (Oct. 14, 2026, 7:33 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:18 a.m. EDT
The immediate outlook is sharply negative, driven by a brutal price collapse that has erased nearly 97% of the company's value over the last three years. While recent headlines celebrate a 'surge' and upbeat growth updates from the CyPath Lung division, the market has overwhelmingly rejected these positives, sending shares tumbling from highs above $80 to under $5 in just months. This disconnect suggests the previous rally was a bubble that has now burst, leaving the stock with severe technical damage and no immediate recovery path. Fundamentally, the business is in distress: it is burning cash aggressively with operating losses exceeding $11 million and negative free cash flow, while relying on a tiny cash pile relative to its debt obligations. The negative beta indicates the stock is highly volatile and moves inversely to the broader market, amplifying downside risk during downturns. With no dividend to provide income and a balance sheet showing significant leverage against shrinking equity, the investment case is currently devoid of safety or catalysts strong enough to overcome the structural deterioration. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.304863 |
| AutoTheta | 0.305162 |
| AutoETS | 0.309527 |
| MSTL | 0.320351 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 0.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.858 |
| Excess Kurtosis | 0.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 38.076 |
| Revenue per Share | 23.198 |
| Market Cap | 4,568,085 |
| Forward P/E | -5.93 |
| Beta | -1.25 |
| Profit Margins | -257.33% |
| Website | https://bioaffinitytech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9108241 |
| Address1 | 3,300 Nacogdoches Road |
| Address2 | Suite 216 |
| All Time High | 6,997.5 |
| All Time Low | 3.23 |
| Ask | 3.58 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 3,803,340 |
| Average Daily Volume3 Month | 3,698,698 |
| Average Volume | 3,698,698 |
| Average Volume10Days | 3,803,340 |
| Beta | -1.254 |
| Bid | 4.75 |
| Bid Size | 1 |
| Book Value | 8.339 |
| City | San Antonio |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.56 |
| Current Ratio | 1.442 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.6786 |
| Day Low | 3.411 |
| Debt To Equity | 38.076 |
| Display Name | bioAffinity |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,174,600 |
| Earnings Timestamp Start | 1,755,174,600 |
| Ebitda | -11,968,556 |
| Ebitda Margins | -2.02823 |
| Enterprise To Ebitda | -0.077 |
| Enterprise To Revenue | 0.157 |
| Enterprise Value | 927,181 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -109.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.1059 |
| Fifty Day Average Change | -3.5458999 |
| Fifty Day Average Change Percent | -0.49900785 |
| Fifty Two Week Change Percent | -91.08241 |
| Fifty Two Week High | 80.7 |
| Fifty Two Week High Change | -77.14 |
| Fifty Two Week High Change Percent | -0.955886 |
| Fifty Two Week Low | 3.23 |
| Fifty Two Week Low Change | 0.32999992 |
| Fifty Two Week Low Change Percent | 0.10216716 |
| Fifty Two Week Range | 3.23 - 80.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,662,039,000,000 |
| Float Shares | 536,748 |
| Forward Eps | -0.6 |
| Forward P E | -5.933333 |
| Free Cashflow | -6,909,285 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 57 |
| Fullday Change | -0.11500001 |
| Fullday Change Percent | -3.172414 |
| Fullday Price | 3.56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.34607 |
| Gross Profits | 2,042,175 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00746 |
| Held Percent Institutions | 0.05053 |
| Implied Shares Outstanding | 1,283,170 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ipo Expected Date | 2,022-08-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,787,529,600 |
| Last Split Factor | 1:15 |
| Long Business Summary | bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas. |
| Long Name | bioAffinity Technologies, Inc. |
| Market | us_market |
| Market Cap | 4,568,085 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_423045573 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -15,185,242 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,715,777 |
| Open | 3.42 |
| Operating Cashflow | -11,468,205 |
| Operating Margins | -2.20767 |
| Phone | 210 698 5334 |
| Post Market Change | -0.049999952 |
| Post Market Change Percent | -1.4044931 |
| Post Market Price | 3.51 |
| Post Market Time | 1,792,020,800 |
| Previous Close | 3.625 |
| Price Hint | 4 |
| Price To Book | 0.42690971 |
| Price To Sales Trailing12 Months | 0.7741225 |
| Profit Margins | -2.5733402 |
| Quick Ratio | 1.24 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0650001 |
| Regular Market Change Percent | -1.79311 |
| Regular Market Day High | 3.6786 |
| Regular Market Day Low | 3.411 |
| Regular Market Day Range | 3.411 - 3.6786 |
| Regular Market Open | 3.42 |
| Regular Market Previous Close | 3.625 |
| Regular Market Price | 3.56 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 120,004 |
| Return On Assets | -1.25114 |
| Return On Equity | -18.60152 |
| Revenue Growth | 0.19 |
| Revenue Per Share | 23.198 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,283,170 |
| Shares Percent Shares Out | 0.099 |
| Shares Short | 115,467 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 43,959 |
| Short Name | bioAffinity Technologies, Inc. |
| Short Percent Of Float | 0.0995 |
| Short Ratio | 0.01 |
| Source Interval | 15 |
| State | TX |
| Symbol | BIAF |
| Total Cash | 2,429,719 |
| Total Cash Per Share | 4.501 |
| Total Debt | 1,435,005 |
| Total Revenue | 5,900,985 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -109.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.2513 |
| Two Hundred Day Average Change | -16.691301 |
| Two Hundred Day Average Change Percent | -0.82420886 |
| Type Disp | Equity |
| Volume | 120,004 |
| Website | https://bioaffinitytech.com |
| Zip | 78,217 |